Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 20/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13798533 | 0.91 | MET (0.63) | MET | |
| SCHEMBL13798535 | 0.90 | MET (0.61) | MET | |
| SCHEMBL13798534 | 0.84 | MET (0.52) | MET | |
| SCHEMBL3262172 | 0.84 | MET (0.70) | MET | |
| SCHEMBL9910350 | 0.83 | MET (1.00) | MET | |
| SCHEMBL2696445 | 0.81 | MET (1.00) | MET | |
| SCHEMBL15309832 | 0.79 | MET (1.00) | MET | |
| SCHEMBL3257877 | 0.77 | MET (0.64) | MET | |
| SCHEMBL15309711 | 0.75 | MET (1.00) | MET | |
| SCHEMBL13798480 | 0.73 | MET (0.75) | MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2162132-A1 | HETEROCYCLIC KINASE MODULATORS | SGX Pharmaceuticals, Inc. (US) | 2010-03-17 | — | — | EP | disclosed |
| US-20090156594-A1 | HETEROCYCLIC KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090156594-A1 | HETEROCYCLIC KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2009-06-18 | — | — | US | disclosed |
| WO-2008144767-A1 | HETEROCYCLIC KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156594-A1 | HETEROCYCLIC KINASE MODULATORS | MAP3K20, MAP4K2, MAP3K13 | MET 721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.